Clementia Pharmaceuticals Inc., of Montreal, said the data monitoring committee for the company's phase II adaptive-design, dose-ranging study of palovarotene for fibrodysplasia ossificans progressiva has completed a planned review of efficacy and safety data from the first cohort of patients in the study. Read More
Gtx Inc., a Memphis, Tenn.-based company that has seen its shares (NASDAQ:GTXI) struggle ever since sharing disappointing results from a phase III study of enobosarm for muscle wasting in non-small-cell lung cancer patients in 2013, said it plans to meet the $1 minimum bid price requirement for continued listing on Nasdaq by effecting a reverse stock split, if necessary. Read More
Corcept Therapeutics Inc., of Menlo Park, Calif., said it issued warrants to accredited investors in two private placements, one that was completed in March 2008 and the other in March 2012. Read More
Perosphere Inc., a private company focused on bringing a broadly applicable anticoagulant reversal agent to market, has won FDA fast track status for the synthetic small molecule ahead of planned phase III studies. Read More
Researchers have reported early data from a clinical trial that used a combination of genomics and immunotherapy to develop personalized dendritic cell vaccines for patients with metastatic melanoma. Read More
HONG KONG – In another blow to the operations of multinational pharmaceutical companies in China, Pfizer Inc. may have to suspend its vaccine business temporarily as it shifts from Prevenar 7 to Prevenar 13. Read More
The latest chapter in the long saga of Repros Therapeutics Inc.'s quest to get an estrogen blocker approved for secondary hypogonadism in overweight men gave investors cause for both optimism and concern, as the FDA's acceptance for filing of the new drug application (NDA) brought questions about the timing of an advisory committee meeting – and what U.S. gatekeepers might want next. Read More
Johnson & Johnson Innovation-JJDC Inc., of New Brunswick, N.J., made a $15 million commitment to Vivo Capital Fund VIII, an investment firm focusing on health care companies in the U.S. and China. Read More
